Cancers in which HER-2/neu protein overexpression occurs include human adenocarcinomas such as breast (in 20–40% of intraductal carcinomas) (Slamon et al, 1987) or ovary (in 30%) (Berchuck et al, 1990). Here, ERBB2 is linked to cancer.